A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT).

Gil Awada Julia Katharina Schwarze Jens TijtgatGiuseppe FasolinoHendrik EveraertBart Neyns

Published in: Cancers (2021)

Combining full-dose trametinib with low-dose dabrafenib can mitigate MEK-inhibitor-related skin toxicity but was insufficiently active in this patient population. This combination can be of further interest for the treatment of MEK-inhibitor-sensitive tumors.

Keyphrases

low dose
clinical trial
high dose
pi k akt
case report
oxidative stress
phase ii
randomized controlled trial
study protocol
open label
double blind
replacement therapy
wild type
oxide nanoparticles